BUSINESS

Tolero Aims to File for AML Treatment Alvocidib in FY2018 in US: Sumitomo Dainippon

March 1, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Tolero Pharmaceuticals, a US biotech startup specializing in cancer and hematologic disorders, which was recently acquired by Sumitomo Dainippon Pharma, aims to submit a new drug application (NDA) for its CDK9 inhibitor alvocidib for acute myeloid leukemia (AML) in the…

To read the full story

Sumitomo Dainippon Completes Tolero Acquisition
January 27, 2017

BUSINESS

Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
Tanabe Starts Long-Term Uplizna Study in IgG4-Related Disease
June 25, 2026
ASKA Shareholders Back Faster Poison Pill Activation
June 25, 2026
EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
Tacrolimus Generics Add Cell Transplantation Indication
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…